Branddocs acquires and merges with TrustCloud – becomes the first global digital transactions choreographer
11.4.2023 12:30:00 EEST | Business Wire | Press release
Branddocs Inc, a prominent provider of secure digital transactions and video verification services, has announced today it is acquiring TrustCloud Inc, the world's first choreographing platform for secure digital transactions, in a move that strengthens its commitment to building trust and confidence in the digital economy.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230411005217/en/
The Capabilities of the TrustCloud Choreography Platform (Graphic: Business Wire)
The newly merged company will trade as TrustCloud; combining former Branddocs’ large client base and its in-house network of fraud detection experts, AI/ML technologies, multi-orchestration capabilities and the widely acclaimed TrustCloud modular platform to deliver a globally compliant, frictionless and vendor-agnostic user journey. Clients include industry leaders such as JPMorgan Chase, Santander, BBVA, Willis Tower Watson, Direct Line and HDI, as well as government entities, healthcare providers and fast-growing Fintech companies, to name but a few.
“Knowing we can now offer one singular SaaS platform with one API and SLA across all our integrated vendors means our clients can now implement truly global and transformational orchestration solutions for every type of digital transaction – from eSignature to IAM and ID verification to the custody of digital assets in TrustCloud Vault. Our plug and play platform prevents the heartache of vendor lock-in, empowering clients with the freedom to choose any provider with per-transaction pricing. Any existing solution can be seamlessly integrated into TrustCloud’s vendor hub, which means zero interruption to our clients’ infrastructure and services,” states Branddocs’ CEO, Christoph Sauerwein.
As the world’s most certified Qualified Trust Service Provider (QTSP), TrustCloud effectively shields clients' global digital ecosystems, ensuring additional security and compliance at every level of transactional orchestration. Its unique choreographic ability allows for seamless management of high transaction volumes across various geographies while still maintaining an agile and adaptable approach.
“TrustCloud's unwavering commitment to building trust, coupled with cutting-edge technology and simplification of processes, enables businesses and consumers to engage in online transactions with greater ease and security. Due to our humanistic approach, by prioritising user control and visibility across the digital journey, we are seeing conversion rates significantly increase for our clients,” says Saioa Echebarria, CEO of TrustCloud.
About TrustCloud
TrustCloud is a secure digital transaction choreographer (SDTC) providing a range of services, including identity verification, authentication and authorization, encryption, digital signature verification, e-vaulting and e-archiving. These services are designed to protect the confidentiality, integrity, and availability of sensitive information, such as personal and financial data, throughout the entire digital transaction process. TrustCloud is also recognised as the most certified Qualified Trust Service Provider (QTSP) globally with certifications including ISO 27001, 17068, 22301, 27017, 27018, 27701, NIST 800-63 & 800-171, SOC2, HIPAA and eIDAS among others.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230411005217/en/
Contact information
For further information visit Trustcloud.tech. For press enquiries email: press@trustcloud.tech
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Europe’s Largest Celebration of Irish Culture Arrives in Belfast2.8.2026 11:01:00 EEST | Press release
Fleadh Cheoil na hÉireann arrives in Belfast today (2 August), bringing eight days of traditional music, culture and celebration to the city, with organisers expecting up to 800,000 visitors over the course of the festival. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260729147569/en/ Belfast Fleadh - Maddens Bar accordian, guitar and fiddle player (Chris Heaney) One of Europe’s largest cultural events, Fleadh Cheoil na hÉireann is taking place in Belfast for the first time, transforming the city into a vibrant stage for Irish music, dance, language and culture. More than 200 events and 180 traditional music competitions are taking place across venues, streets and neighbourhoods throughout the week-long celebration. The landmark festival showcases the very best of Irish culture, with a packed programme of All-Ireland competitions, concerts, community events and performances from both established and emerging artists. As Ir
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 14:42:00 EEST | Press release
2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (Photo: AETOSWire) Net profit from the Group’s businesses increased by 2,301% year-on-year (YoY), driven by the consolidation of Tendam and the mega-merger to form 2PointZero Group, and growth was also supported by new investments in African financial services, entry into the European packaging markets, and steady operational progress across all verticals, bringing the total reported net profit to AED 7.7 billion. Through continued operational integr
Datroway ® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 09:30:00 EEST | Press release
Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from the TROPION-Breast02phase 3 trial, which were presented at the 2025 European Society for Medical Oncology Congress and subsequently published in Annals of Oncology. In TROPION-Breast02, which included patients with metastatic TNBC who experienced early relapse following prior treatment, Datroway demonstrated a statis
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 09:30:00 EEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
Half-Year Report on SES’s Liquidity Contract31.7.2026 08:30:00 EEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom